When was NeuroEM founded?

NeuroEM was founded in 2013 and raised its 1st funding round 3 years after it was founded.

Where is NeuroEM located?

NeuroEM is headquartered in Tampa, United States.

How many employees does NeuroEM have?

As of Aug 31, 2026, the latest employee count at NeuroEM is 11.

Is NeuroEM a funded company?

NeuroEM is a funded company, having raised a total of $9M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 19, 2016.

When was the latest funding round of NeuroEM?

NeuroEM's latest funding was a $***** Series A round on Apr 09, 2025, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.05B in funding in 2026 to date.

Where does NeuroEM rank among its competitors?

NeuroEM ranks 10th amongst 166 active competitors, of which 38 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was BrainCo, which secured an undisclosed amount in Sep, 2026.

Who are the top competitors of NeuroEM?

NeuroEM's top competitors include Ceribell, Cognito Therapeutics and Cala Health. Among them, BrainCo secured the most recent funding round in September, 2026.

NeuroEM - 2026 Company Profile, Funding & Competitors

NeuroEM is a series A company based in Tampa (United States), founded in 2013. It operates as a Developer of medical device a non-invasive treatment for cognitive decline. NeuroEM has raised $9M in funding from Bluelake. The company has 166 active competitors, including 38 funded and 5 that have exited. Its top competitors include companies like Ceribell, Cognito Therapeutics and Cala Health.

Company Details

Developer of medical device a non-invasive treatment for cognitive decline. The company is pioneering the use of Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) with its patented wearable device called MemorEM that delivers electromagnetic waves through a head cap to break up toxic proteins beta-amyloid and p-tau, which are believed to underlie Alzheimer's disease. As of July 2016, it has been tested in animals and has shown no adverse effects. Human trials have already began.

Key Metrics

Founded Year

2013

Location

Tampa, United States

Stage

Series A

Total Funding

$9M in 4 rounds

Latest Funding Round

Series A, Apr 09, 2025, $*****

Investors

Bluelake & 2 more

Ranked

10^th among 166 active competitors

Employee Count

11 as on Aug 31, 2026

Similar Companies

Ceribell & 167 more

View NeuroEM's full profile

NeuroEM has raised a total funding of $9M over 4 rounds. Its first funding round was on Feb 19, 2016. Its latest funding round was a Series A round on Apr 09, 2025 for $*****. 1 investor participated in its latest round. NeuroEM has 3 institutional investors.

Here is the list of recent funding rounds of NeuroEM:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 09, 2025	2709694	Series A	7103223	4865692	6052935	4849373
May 31, 2024	9546278	Seed	8625860	9416221	6944050	6531409
Dec 15, 2016	7346917	Grant (prize money)	9755945	4161726	5611666	HHS

Access funding benchmarks and valuations. Sign up today!

View details of NeuroEM's funding rounds and investors

NeuroEM's employee count trend

NeuroEM has 11 employees as of Aug 26. Here is NeuroEM's employee count trend over the years:

Uncover NeuroEM's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NeuroEM include Ceribell, Cognito Therapeutics and Cala Health. Here is the list of Top 10 competitors of NeuroEM, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Ceribell 2014, Mountain View (United States), Public	EEG system for the diagnosis of seizures	$188M	The Rise Fund, Longitude Capital & 11 others	69/100
2nd	Cognito Therapeutics 2016, Cambridge (United States), Series C	Developer of a medical device for the treatment of Alzheimer's disease	$420M	Morningside, FoundersX Ventures & 10 others	65/100
3rd	Cala Health 2013, Stanford (United States), Series D	Developer of a wearable non-invasive neuromodulation device	$257M	Vertex Growth, Novartis & 29 others	63/100
4th	BrainCo 2015, Somerville (United States), Series B	Provider of a prosthetic hand and EEG headband for brain signal	$292M	Walden International, IDG Capital & 10 others	58/100
5th	Kernel 2016, Los Angeles (United States), Series C	Developer of multimodal brain measurement technology for neuromedicine	$158M	General Catalyst, Eldridge Industries & 3 others	57/100
6th	Grey Matter Neurosciences 2021, Toronto (Canada), Seed	Developer of medical devices for neurological disease treatment	$14M	Wittington Ventures, Ontario Centre of Innovation ... & 2 others	55/100
7th	Halo 2013, San Francisco (United States), Acquired	Online platform offering wearable brain cortex stimulator to improve exercise performance	$61.7M	TPG, FJ Labs & 13 others	54/100
8th	Welltok 2009, Denver (United States), Acquired	Provider of cloud-based employee wellness platform	$312M	Georgian, Emergence Capital & 30 others	51/100
9th	Sense Neuro Diagnostics 2013, Cincinnati (United States), Seed	Non-invasive brain activity monitoring device	$4.64M	Queen City Angels, Defense.gov & 3 others	51/100
10th	NeuroEM 2013, Tampa (United States), Series A	Developer of medical device a non-invasive treatment for cognitive decline	$9M	New York Angels, HHS & 1 others	50/100